Loading...
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA approved for treatment of Paroxysmal Nocturnal Hemo...
Saved in:
| Published in: | Front Immunol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Frontiers Media S.A.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7793867/ https://ncbi.nlm.nih.gov/pubmed/33424866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.612402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|